Roche "buy"

01/11/06 - Jyske Bank

LONDON, January 11 (newratings.com) - Analysts at Jyske Bank maintain their "buy" rating on Roche (ROG). The target price is set to CHF235.

In a research note published this morning, the analysts mention that the company is expected to post robust results for 2005, which would lend upside to its share price in the near term. The sales of Roche's Herceptin drug for the treatment of breast cancer are likely to have been ahead of expectations, the analysts say. The company’s cancer drug franchise has a robust product pipeline, Jyske Bank adds.